Objective: To examine the efficacy of docetaxel, carboplatin plus trastuzumab regimen (TCH) as neoadjuvant setting in early-stage human epidermal growth factor receptor 2 (HER2) positive breast cancer. Methods: Totally 522 patients diagnosed with early-stage HER2 positive breast cancer at Breast Disease Center, Peking University First Hospital between January 2013 to December 2018 were enrolled, which constituted 21.8% (522/2 394) of early-stage invasive breast cancer. Clinical pathological factors were retrospectively analyzed. There were 113 female patients underwent TCH neoadjuvant chemotherapy, aging 52(13) years (range: 23 to 69 years). Pathologic complete pathological response(pCR) was defined as ypT0N0M0, and the rate of pCR was calculated. Kaplan-Meier method and Log-rank test were used for survival comparison. Results: Patients who received trastuzumab-based therapy(n=294) had higher disease-free survival (DFS) compared with those who omitted trastuzumab(n=177) (84.4% vs. 72.4%, χ²=4.095, P=0.046). Eighteen of 113 patients (15.9%) experienced grade 3 to 4 chemotherapy-realted toxicity. Grade 3 to 4 neutropenia occurred in 12 patients, while grade 3 to 4 diarrhea occurred in 6 patients. Thirty-one of 113 (27.4%) patients achieved pCR. DFS and overall survival (OS) were similar between patients who achieved pCR and non-pCR (DFS: 91.8% vs. 85.0%, OS: 92.5% vs. 90.5%, all P>0.05). According to Miller-Payne system, patients who achieved G4 to G5 had improved DFS compared with G1 to G3 (89.6% vs. 81.5%, χ²=5.340, P=0.021), but they had similar OS (91.4% vs. 89.1%, χ²=1.008, P=0.315). Conclusions: TCH is an effective regimen in neoadjuvant setting for patients with HER2 positive breast cancer. Patients who achieved G4 to G5 had improved DFS.
目的： 探讨多西他赛+卡铂联合曲妥珠单抗（TCH）方案对早期人表皮生长因子受体2（HER2）阳性乳腺癌的新辅助治疗效果。 方法： 回顾性分析2013年1月至2018年12月北京大学第一医院乳腺疾病中心经治的522例早期HER2阳性乳腺癌患者的临床资料，占同期收治早期浸润性乳腺癌患者的21.80%（522/2 394）。其中113例接受TCH方案进行新辅助治疗，年龄［M（QR）］52（13）岁（范围：23~69岁）。记录TCH方案新辅助治疗后病理完全缓解（pCR，ypT0N0M0期）的例数，采用Miller-Payne标准进行病理学评价。采用Kaplan-Meier法计算无病生存率和总体生存率，采用Log-rank检验比较组间生存差异。 结果： 接受曲妥珠单抗规范治疗患者（294例）的无病生存率优于未规范治疗患者（177例）（84.4%比72.4%，χ²=4.095，P=0.046）。发生3~4级不良反应的患者占全部患者的15.9%（18/113），包括3~4级中性粒细胞减少12例，腹泻6例。31例患者获得pCR（ypT0N0M0），pCR率为27.4%（31/113）。pCR患者与非pCR患者的无病生存率和总体生存率无差异（91.8%比85.0%，92.5%比90.5%，P值均>0.05）。病理学评价为G4~5的患者无病生存率优于G1~3患者（89.6%比81.5%，χ²=5.340，P=0.021），而总体生存率的差异无统计学意义（91.4%比89.1%，χ²=1.008，P=0.315）。 结论： 早期HER2阳性乳腺癌采用TCH方案行新辅助治疗的效果较好，新辅助治疗后病理学评价为G4~5的患者的无病生存率更高。.